DrugPatentWatch Database Preview
T - Profile
Email this page to a colleague
» See Plans and PricingUS Patents for t
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thrombogenics, Inc | JETREA | ocriplasmin | INJECTABLE; INTRAVITREAL | 125422 | 001 | 2012-10-17 | 9,730,888 | Wayne State University (Detroit, MI) | 2033-03-14 | RX | search | |
| Thrombogenics, Inc | JETREA | ocriplasmin | INJECTABLE; INTRAVITREAL | 125422 | 001 | 2012-10-17 | 9,603,739 | OcuJect, LLC (Newport Beach, CA) | 2032-04-02 | RX | search | |
| Thrombogenics, Inc | JETREA | ocriplasmin | INJECTABLE; INTRAVITREAL | 125422 | 001 | 2012-10-17 | 9,504,603 | OcuJect, LLC (Newport Beach, CA) | 2032-04-02 | RX | search | |
| Thrombogenics, Inc | JETREA | ocriplasmin | INJECTABLE; INTRAVITREAL | 125422 | 001 | 2012-10-17 | 9,474,688 | Corning Incorporated (Corning, NY) | 2031-10-25 | RX | search | |
| Thrombogenics, Inc | JETREA | ocriplasmin | INJECTABLE; INTRAVITREAL | 125422 | 001 | 2012-10-17 | 9,421,129 | OcuJect, LLC (Newport Beach, CA) | 2032-04-02 | RX | search | |
| Thrombogenics, Inc | JETREA | ocriplasmin | INJECTABLE; INTRAVITREAL | 125422 | 001 | 2012-10-17 | 7,914,783 | ThromboGenics NV (Heverlee, BE) | 2022-12-06 | RX | company | |
| Thrombogenics, Inc | JETREA | ocriplasmin | INJECTABLE; INTRAVITREAL | 125422 | 001 | 2012-10-17 | 7,547,435 | ThromboGenics NV (Leuven, BE) | 2022-12-06 | RX | company | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
